AbSci
2011
FOUNDED
PRIVATE
STATUS
21-30
EMPLOYEES
Series D
LATEST DEAL TYPE
$15.4M
LATEST DEAL AMOUNT
13
INVESTORS
Description
Operator of a biotechnology company intended to produce proteins for biotherapeutic medical treatments. The company specializes in the production of soluble, disulfide proteins ranging from monoclonal antibodies to insulin in a semi-oxidized cytoplasm through secretion into the periplasmic space, thereby allowing the healthcare industry to mass-produce medical compounds.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 101 East 6th Street
- Suite 350
- Vancouver, WA 98660
- United States
+1 (360) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore AbSci’s full profile, request a free trial.
AbSci Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series D) | 18-Dec-2019 | $15.4M | 000.00 | Completed | Generating Revenue | |
| 6. Later Stage VC (Series C) | 30-May-2018 | 0000 | 000.00 | Completed | Generating Revenue | |
| 5. Later Stage VC (Series B) | 07-Aug-2017 | 00.00 | Completed | Generating Revenue | ||
| 4. Early Stage VC (Series A) | 11-Apr-2016 | 00.00 | 00.00 | 0000 | Completed | Generating Revenue |
| 3. Accelerator/Incubator | 01-Jan-2013 | Completed | Generating Revenue | |||
| 2. Grant | Completed | Generating Revenue | ||||
| 1. Angel (individual) | Completed | Generating Revenue |
AbSci Competitors (28)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| BioVision | Formerly VC-backed | Milpitas, CA | 000 | 000000&0 | ||
| 00000 0000000000 | Formerly VC-backed | San Francisco, CA | 000 | 00000 | 00000000 | 00000 |
| 000000000 | Corporation | San Diego, CA | 000 | |||
| 00000000 | Venture Capital-Backed | Düsseldorf, Germany | 0000000000 | |||
| 000000 00000000000 | Venture Capital-Backed | Quebec, Canada | 000.00 | 0000000000 | 000.00 |
AbSci Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| JSR Life Sciences | Other | Minority | 000 0000 | 000000 0 | ||
| KBI BioPharma | Corporation | Minority | 000 0000 | 000000 0 | ||
| AGC (Tokyo) | Corporation | Minority | 000 0000 | 000000 0 | ||
| Columbia Ventures | PE/Buyout | Minority | 000 0000 | 000000 0 | ||
| Greenbridge Partners | Other | Minority | 000 0000 | 000000 0 |
AbSci Executive Team (5)
AbSci Board Members (6)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Bryan Lawlis | AbSci | Board Member | 000 0000 | |
| Daniel Gold Ph.D | AbSci | Board Member | 000 0000 | |
| Gustavo Mahler Ph.D | Self | Board Member | 000 0000 | |
| Loretta Little | WRF Capital | Board Member | 000 0000 | |
| Sean McClain | AbSci | Co-Founder, Chief Executive Officer and Board Member | 000 0000 |